EE108 Cost-Effectiveness Analysis of Abrocitinib Versus Dupilumab for Treatment of Moderate-to-Severe Atopic Dermatitis in Chinese Adults
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.378
https://www.valueinhealthjournal.com/article/S1098-3015(23)03508-8/fulltext
Title :
EE108 Cost-Effectiveness Analysis of Abrocitinib Versus Dupilumab for Treatment of Moderate-to-Severe Atopic Dermatitis in Chinese Adults
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03508-8&doi=10.1016/j.jval.2023.09.378
First page :
Section Title :
Open access? :
No
Section Order :
12406